PROM1 and breast neoplasm: More recently, the overexpression of both CD133 mRNA and protein were investigated in large well-characterized BC cohorts, resulting particularly high in TNBC and HER2+ tumors and confirming the negative prognostic value of CD133 in all breast tumor subtypes [26].